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sUMMAry – Accurate assessment of Her-2 status is essential for identifying patients who 
will benefit from Her-2 targeted therapy. The aim of the present study was to show results on the 
concordance between local and central laboratory testing results in Her-2 positive breast cancer pa-
tients. In cases with discordant findings, the immunohistochemical (IHC) and/or in situ hybridiza-
tion (FIsH/sIsH) analysis was performed in central laboratories. A total of 104 out of 143 (72.72%) 
breast carcinoma cases were Her-2 positive (score 3+), while nearly 14% of tumors (20/43) showed 
weak (score 2+) and 12% (19/143) negative IHC staining (score 0 and 1+). After repeated IHC and 
IsH, 88% (126/143) were classified as Her-2 positive and 12% (17/143) as Her-2 negative cases. 
The results obtained are in agreement with many studies that confirmed similar discordance in 
Her-2 testing by IHC and/or FIsH between local and central laboratory. Thus, our findings as 
well as those from other studies support the importance of regular quality assessment of the staining 
procedures performed and consistency of interpretation of Her-2 test results. 
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Introduction
breast cancer is the most common malignancy in 
women, affecting approximately 2500 women per year 
in Croatia1. Although substantial progress has been 
made, one-third of patients with breast carcinoma 
will have poor prognosis. The disease shows variable 
biological and clinical behavior. besides the classic 
prognostic factors used in clinical practice, Human 
epidermal Growth Factor  receptor 2 (Her-2/neu, 
erbb2), a proto-oncogene located on chromosome 
17, has become an important prognostic indicator2. 
Her-2 protein, as member of the epidermal growth 
factor receptors, located on the cell membrane, is in-
volved in signal transduction for proliferation, differ-
entiation, adhesion and motility of epithelial cells3. 
Thus, overexpression of these proteins in patients with 
breast cancer and positive lymph nodes is associated 
with poor prognosis with a reduced disease-free inter-
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val and shortened survival time, and similar linkage 
may exist in node-negative cases4-6.
trastuzumab (Herceptin), a humanized mono-
clonal anti-Her-2 antibody, has been approved by 
the Us Food and drug Administration (FdA) as an 
adjuvant therapeutic agent for breast cancer patients 
with positive Her-2 status7,8. Amplification of the 
Her-2 gene is the underlying molecular abnormal-
ity that causes overexpression of the Her-2 protein 
on the cell surface in approximately 15% to 20% of 
primary breast cancers9-11. determination of Her-2 
status prior to therapeutic interventions has become a 
standard practice for the management of breast can-
cer. The evaluation of Her-2 status has become piv-
otal to determining patient eligibility for Her-2 tar-
geted therapy, since clinical benefit from this therapy 
can only be expected in patients with Her-2 positive 
tumor12,13.
In clinical laboratory, Her-2 status usually is as-
sessed on formalin-fixed and paraffin-embedded tis-
sue using either immunohistochemistry (IHC) or in 
situ hybridization (IsH) assay to measure Her-2 
protein on the cell membrane and Her-2 gene cop-
ies, respectively. Considering the important predictive 
value of this assessment, quality control of the labora-
tories performing Her-2 testing is necessary. In Cro-
atia, there are more than 10 laboratories performing 
IHC and 7 laboratories performing IsH in testing for 
Her-2 status. In the last ten years, several national 
ring studies and inter-laboratory quality controls of 
Her-2 staining and scoring have been performed. 
The aim is to present results of the last study ana-
lyzing inter-laboratory concordance between local and 
central laboratories analyzing Her-2 positive breast 
cancer samples and to discuss them according to lit-
erature data. 
Patients and Methods
The study included ten laboratories from Croatia 
where IHC testing for Her-2 status was performed 
during 2011 for a total of 143 patients. local labora-
tories performed IHC staining for determination of 
Her-2 status using the Herceptest (dako, Carpin-
teria, CA, UsA), according to the manufacturer’s 
instructions. Paraffin-embedded breast tumor blocks 
and IH stained sections, evaluated as 3+ in local labo-
ratories, were submitted to central laboratory. 
In central laboratory, reevaluation of Her-2 score 
was performed. In those cases in which IHC score 3+ 
was not confirmed, two protocols were used, accord-
ing to the scheme shown in Figure 1. 
Immunohistochemical analysis at central laboratory
Paraffin blocks from the slides that showed nega-
tive (0) or weak, discontinuous membrane staining 
(1+) were chosen for IHC analysis. serial 4- to 5-µm 
thick sections were used for IHC using dAKo Her-
ceptest kit and the results were interpreted according 
to the American society of Clinical oncology/Col-
lege of American Pathologists (AsCo/CAP) guide-
lines from 200714. 
In situ hybridization at central laboratory 
In situ hybridization with sIsH or FIsH method 
was performed in the cases with IHC score evaluated 
as 2+. The Path vysion Her-2 probe kit was used for 
FIsH analysis. In brief, the sections were baked over-
night at 56 oC and the invasive carcinoma components 
were marked based on the corresponding He stained 
sections. Unstained sections were deparaffinized in 
Citrisolv (vysis), dehydrated in 100% ethanol, and 
air dried. Then the slides were subjected to protease 
digestion for 45 to 60 min, denatured, and hybridized 
with prewarmed probe for Her-2 gene and chromo-
some 17 centromere (Her2/neu/CeP17 sG probe, 
vysis) overnight at 37 oC. Then they were washed 
Fig. 1. Schematic diagram summarizes the numbers of 
breast cancer specimens received and analyzed by immu-
nohistochemistry (IHC), silver in situ or fluorescent in situ 
hybridization (SISH/FISH) in central laboratories (Split 
and Rijeka).
Local test result IHC 3+
submitted to central lab
N=143
IHC performed
in central lab
N=19
SISH/FISH
performed in central lab
N=20
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with posthybridization wash buffer at 72 ºC and 
counterstained with 4.6-diamidino-2-phenylindole 
(dAPI) in antifade solution, mounted and scored. 
slides were first scanned at low magnification (x100) 
using dAPI filter to identify areas of optimal tissue 
digestion and no overlapping nuclei within the area 
of invasive carcinoma. The signal enumeration was 
performed under high magnification (x1000). The 
number of chromosome 17 signals, Her-2 signals, 
and tumor nuclei score were recorded for each tumor. 
tumors were interpreted as amplified, positive when 
the ratio of Her-2 signals divided by chromosome 
17 centromere was equal to or greater than 2.0 and 
negative when it was less than 2.0 according to the 
manufacturer’s protocol. 
The ventana InForM Her2 dual sIsH probe 
was used for dual sIsH analysis, using fully auto-
mated protocol developed on the ventana benchMark 
Xt. In the invasive area, at least 20 cells were counted, 
recording the Her2 and CHr17 results from each 
nucleus. At the end, the Her2/CHr17 ratio was cal-
culated. staining results were scored according to the 
AsCo/CAP guidelines from 200714.
Results
Clinicopathologic characteristics of patients 
The clinical and pathological characteristics of pa-
tients with Her-2 positive invasive breast cancer in-
volved in this study are summarized in table 1. Most 
of the patients (nearly 30%) were between 50 and 60 
years old, with pathological tumor size between 2 and 
5 cm (pt2) (around 44%), and with high grade car-
cinoma in most cases (55%). In addition, most of the 
tumors (43% of cases) showed high proliferative activ-
ity (>30%) measured by Ki67 antibody (43%) and lym-
Fig. 2. Cases with insufficient and false-positive immunohistochemical staining for HER-2 protein in duc-
tal breast carcinomas (A, B); insufficient staining due to retraction of stroma and developed clefts in which 
the chromogen precipitated. False-positive staining at tumor margins that would not be evaluated (C, D). 
482 Acta Clin Croat,  Vol. 54,   No. 4,  2015
Nives Jonjić et al. Interlaboratory concordance in HER-2 positive breast cancer
phovascular invasion (56%). According to the steroid 
receptor status, most tumors were estrogen receptor 
(er) positive (61%) and progesterone receptor (Pr) 
negative (56%). 
Concordance between local and central laboratory
reevaluation of IHC stained slides in central lab-
oratory showed that 104 (72.72%) out of 143 breast 
carcinomas were strongly Her-2 positive (score 3+), 
while nearly 14% of tumors (20/43) showed weak 
(score 2+) and 12% (19/143) negative (score 1+ and 0) 
staining (table 2). Figure 2 presents some representa-
tive cases with false-positive score at tumor margins 
or strong reaction in the clefts. 
The results of repeated IHC at central laboratory 
are summarized in table 3. eleven of 19 (59%) cases 
showed strong membrane staining (3+), while the re-
maining 8 cases were classified as weak (2+?) or nega-
tive (0 and 1+). Among 2+ tumors (20/143) that were 
selected for IsH, Her-2 gene was amplified in 11 of 
20 (55%) cases, while no amplification was found in 9 
of 20 (45%) cases. 
Final results, after repeated IHC and performed 
IsH, are summarized in table 3. Most of the tumors 
(126/143 or 88%) were Her-2 positive, while 12% 
(17/143) were negative. 
Discussion
Her-2 protein overexpression and/or gene ampli-
fications are prognostic for patients with node-positive 
and node-negative breast cancers, predictive of some 
chemotherapeutic and hormonal agents, and an indi-
cation for Her-2 targeted therapy4-6. However, the 
risk of cardiac toxic effects and the spectrum of pa-
tients with false-positive results accruing into breast 
cancer clinical trials have drawn attention to the sen-
sitivity and specificity of clinical Her-2 assays. The 
last guidelines drafted by the AsCo/CAP have high-
Table 1. Patient and tumor characteristics in HER-2 pos-
itive invasive breast cancers enrolled in the study
Characteristic  n (%)
Age at diagnosis (yrs)
20-30
31-40
41-50
51-60
61-70
71-80
>80
3 (1.97)
6 (3.95)
17 (11.18)
50 (32.9)
39 (25.66)
33 (21.71)
4 (2.63)
tumor size
t1a
t1b
t1c
t2
t3
1 (0.65)
12 (7.74)
49 (31.61)
68 (43.87)
25 (16.13)
Histologic grade
I
II
III
3 (1.96)
66 (43.13)
84 (54.91)
Ki67 index
1%-14%
15%-30%
>30%
23 (15.54)
62 (41.89)
63 (42.57)
lvI
no
yes
30 (44.12)
38 (55.88)
er
negative
Positive
61 (38.85)
96 (61.15)
Pr
negative
Positive
88 (56.05)
69 (43.95)
lvI = lymphovascular invasion; er = estrogen receptor; Pr = 
progesterone receptor
Table 2. Comparative evaluation of HER-2 protein expression by immunohistochemistry 
(IHC) assay 3+ score of invasive component of a breast cancer specimen between central 
laboratory and local laboratories 
outside lab
IHC score 3+
                         Central lab IHC score
0 1 2 3 total
n (%) n (%) n (%) n (%) n (%)
2 (1.4) 17 (11.9) 20 (13.9) 104 (72.8) 143 (100)
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lighted that up to now 15% to 20% of current Her-2 
testing are inaccurate, thus significantly affecting 
therapeutic decision making15. so, how to best assess 
Her-2 status in breast cancer is an important issue, 
particularly after the Us FdA has approved the use of 
trastuzumab that targets Her-2 protein7,8. 
two types of IHC test to determine Her-2 status 
are approved by the FdA: Herceptest (dako, Carpin-
teria, CA, UsA) and Pathway (ventana Medical sys-
tem Inc., tucson, AZ, UsA). More recently, FIsH/
sIsH, which directly measures Her-2 gene amplifi-
cation, has been added to the armamentarium of tests 
that can be used to identify patients with Her-2 pos-
itive tumor for trastuzumab therapy. The hallmark of 
Her-2 abnormality in breast cancer is protein over-
expression, which in most cases apparently occurs as 
the result of the corresponding gene amplification9-11. 
Consequently, either IHC assay or FIsH has been ex-
plored as a single assay to evaluate respective Her-2 
protein or gene status. In many studies, good concor-
dance from 89% to 93% was found between the group 
scored as IHC 3+ and FIsH results15-18. nonetheless, 
some authors consider the IsH to be a more accurate 
and consistent scoring system for determining Her-2 
amplification than Hercep test19. In addition, accord-
ing to some authors’ experience, IsH studies should 
be performed on all 3+ and 2+ staining to avoid inap-
propriate and toxic treatment20. Most data support an 
algorithm in which IsH testing is restricted to IHC 
2+ tumors21. IsH is more time consuming and expen-
sive than IHC, and is therefore not preferred for pri-
mary screening for Her-2 status22. 
The quality of the staining procedures performed 
and consistency of interpretation require regular as-
sessment. Many international ring studies were con-
ducted to investigate the quality of Her-2 testing23-
27. In our country, in the last ten years, several national 
ring studies were also performed in order to evaluate 
Her-2 staining and interpretation reproducibility 
among participants. The present study was designed 
with the aim to demonstrate agreement in IHC 
Her2 3+ scoring between the coordinating institu-
tion and 10 participating laboratories. All laboratories 
used Herceptest for IHC analysis, whereas IsH was 
performed by FIsH and sIsH assays in two laborato-
ries. repeated IHC done at central laboratory proved 
the strong positive IHC 3+ result by Herceptest in 
82 of 104 (79%) cases, while Her2 gene amplifica-
tion was confirmed with FIsH/sIsH in 126 of 143 
(88.1%) cases. similarly, the breast Intergroup report 
for protocol n9831 describing the first 119 women 
with 3+ IHC immunostaining at the accruing insti-
tution shows that only 74% were 3+ by Herceptest 
done centrally23. When local and central evaluation 
used the same methodology, concordance was 81.6% 
for IHC25. The sources of error are most likely primar-
ily preanalytical. For example, IHC testing can yield 
false-negative results when the Her-2 epitope is de-
stroyed by formalin fixation. This process may occur 
in up to 20% of Her-2 positive samples and can be 
problematic when testing archive samples that have 
been stored long term (e.g., when testing primary tu-
mor samples at relapse). Conversely, variability in tis-
sue processing, the reagent used and antigen retrieval 
can contribute to false-positive IHC results. However, 
interpretation of results may also be a key factor, espe-
cially in low-volume testing laboratories.
discordant inter-laboratory results found in our 
study are in line with literature data. external qual-
ity assurance studies emphasize the need of rigorous 
application of standardized procedures with reliable 
and reproducible diagnostic Her-2 testing for pre-
cise identification of breast cancer patients eligible for 
Her-2 targeted therapy.
Table 3. Results of HER-2 status confirmed in central laboratories on stained immunohis-
tochemical (IHC) sections and after repeated IHC staining or in situ hybridization (SISH/
FISH) analysis 
IHC sIsH/FIsH repeated IHC total
n (%) n (%) n (%) n (%)
Her-2 positive 104 (72.8) 11 (55) 11 (57.9) 126 (88.1)
Her-2 negative 39 (27.2) 9 (45) 8 (42.1) 17 (11.9)
total 143 (100) 20 (100) 19 (100) 143 (100)
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sažetak
MeĐU-lAborAtorIJsKA PodUdArnost Her-2 PoZItIvnIH KArCInoMA doJKe
N. Jonjić, E. Mustać, S. Tomić, J. Jakić Razumović, B. Šarčević, V. Blažičević, L. Peteh Labinac, D. Švagelj, A. Kopjar, N. 
Lisica Šikić, B. Vrbičić i I. Borić
Ispravna procjena Her-2 statusa je osnova za pronalaženje bolesnika kojima će koristiti Her-2 ciljana terapija. Cilj 
istraživanja je bio prikazati rezultate podudarnosti između testiranja Her-2 pozitivnih bolesnika oboljelih od raka doj-
ke pri mjesnom i centralnom laboratoriju. U slučajevima nepodudarnih rezultata analize imunohistokemije (IH) i/ili in 
situ hibridizacije su se izvodile u centralnim laboratorijima. Ukupno 104 od 143 (72,72%) slučaja karcinoma dojke su bili 
Her-2 pozitivni (biljeg 3+), dok je skoro 14% tumora (20/43) prikazalo nisko (biljeg 2+) i 12% (19/143) negativno imuno-
histokemijsko bojenje (biljeg 0 i 1+). nakon ponovljene analize IH i IsH 88% (126/143) se klasificiralo kao Her-2 pozi-
tivni i 12% (17/143) kao Her-2 negativni slučajevi. dobiveni rezultati su sukladni mnogim istraživanjima koja potvrđuju 
slične nepodudarnosti pri Her-2 testiranju imunohistokemijom i/ili FIsH analizom između mjesnog i centralnog labo-
ratorija. Prema tome, naši rezultati kao i rezultati drugih istraživanja podupiru značenje pravilnog procjenjivanja izvođenja 
protokola bojenja i dosljednosti interpretacija rezultata Her-2 testiranja.
Ključne riječi: Rak dojke; HER-2; Imunohistokemija; In situ hibridizacija, fluorescentna; Kontrola kvalitete
